Literature DB >> 19007860

Glycogen synthase kinase-3beta is associated with Parkinson's disease.

Masahiro Nagao1, Hideaki Hayashi.   

Abstract

We immunohistochemically examined the expression of glycogen synthase kinase-3beta (GSK-3beta) in the brains of Parkinson's disease (PD) patients. GSK-3beta was localized in punctate structures in the cytosol of subsets of neurons in the midbrain and upper pons. GSK-3beta was also localized in Lewy bodies (LBs) as was phosphorylated GSK-3beta (Ser9) (pGSK-3beta (Ser9)). Both GSK-3beta and pGSK-3beta (Ser9) were localized specifically in the halo of LBs. The core of LBs was negative for GSK-3beta, while pGSK-3beta (Ser9) was present in only a small number of LB cores. Cortical LBs were positive for pGSK-3beta (Ser9) but not for GSK-3beta. Neither GSK-3beta nor pGSK-3beta (Ser9) was present in glial cytoplasmic inclusions (GCIs) in the brains of multiple system atrophy (MSA) patients. Our results suggest that GSK-3beta plays a role in the pathogenesis of PD but not in that of MSA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007860     DOI: 10.1016/j.neulet.2008.10.104

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

1.  PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.

Authors:  Ravi S Akundi; Lianteng Zhi; Hansruedi Büeler
Journal:  Neurobiol Dis       Date:  2011-09-16       Impact factor: 5.996

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

3.  Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.

Authors:  Daniella Balduino Victorino; Mariana Nejm; Marcia Guimarães-Marques; Fulvio Alexandre Scorza; Carla Alessandra Scorza
Journal:  Pharmaceut Med       Date:  2021-01-07

4.  Comparative study of Hsp27, GSK3β, Wnt1 and PRDX3 in Hirschsprung's disease.

Authors:  Hong Gao; Xiaomei Liu; Dong Chen; Liangying Lv; Mei Wu; Jie Mi; Weilin Wang
Journal:  Int J Exp Pathol       Date:  2014-04-29       Impact factor: 1.925

5.  Parkinson's disease-associated DJ-1 mutations increase abnormal phosphorylation of tau protein through Akt/GSK-3β pathways.

Authors:  Yangang Wang; Weiping Liu; Xiaosheng He; Fei Zhou
Journal:  J Mol Neurosci       Date:  2013-08-27       Impact factor: 3.444

6.  GSK-3 in Neurodegenerative Diseases.

Authors:  Peng Lei; Scott Ayton; Ashley I Bush; Paul A Adlard
Journal:  Int J Alzheimers Dis       Date:  2011-05-04

7.  Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice.

Authors:  Ravi S Akundi; Zhenyu Huang; Joshua Eason; Jignesh D Pandya; Lianteng Zhi; Wayne A Cass; Patrick G Sullivan; Hansruedi Büeler
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

Review 8.  GSK-3β at the Intersection of Neuronal Plasticity and Neurodegeneration.

Authors:  Tomasz Jaworski; Ewa Banach-Kasper; Katarzyna Gralec
Journal:  Neural Plast       Date:  2019-05-02       Impact factor: 3.599

Review 9.  Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.

Authors:  Nicolas Dzamko; Jinxia Zhou; Yue Huang; Glenda M Halliday
Journal:  Front Mol Neurosci       Date:  2014-06-24       Impact factor: 5.639

10.  Gsk3β and Tomm20 are substrates of the SCFFbxo7/PARK15 ubiquitin ligase associated with Parkinson's disease.

Authors:  Felipe Roberti Teixeira; Suzanne J Randle; Shachi P Patel; Tycho E T Mevissen; Grasilda Zenkeviciute; Tie Koide; David Komander; Heike Laman
Journal:  Biochem J       Date:  2016-08-08       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.